Perioperative medication management for the patient with rheumatoid arthritis

Journal of the American Academy of Orthopaedic Surgeons

Volumn 14, Issue 9, 2006, Pages 544-551

  Howe, Christopher R ^a,b   Gardner, Gregory C ^a   Kadel, Nancy J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845478729     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-200609000-00004     Document Type: Review

References (40)

1. Luessenhop CP, Higgins LD, Brause BD, Ranawat CS: Multiple prosthetic infections after total joint arthroplasty: Risk factor analysis. J Arthroplasty 1996;11:862-868.
2. Vane JR, Rotting RM: The mechanism of action of aspirin. Thromb Res 2003;110:255-258.
3. Abramson S, Weissmann G: The mechanisms of action of nonsteroidal antiinflammatory drugs. Clin Exp Rheumatol 1989;7(suppl3):S163-S170.
4. Robinson CM, Christie J, Malcolm-Smith N: Nonsteroidal antiinflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993;8:607-610.
5. Samama CM, Bastien O, Forestier F, et al: Antiplatelet agents in the perioperative period: Expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001. Summary statement. Can J Anaesth 2002;49:S26-S35.
6. Smith MS, Muir H, Hall R: Perioperative management of drug therapy, clinical considerations. Drugs 1996;51:238-259.
7. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
8. Romsing J, Moiniche S: A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand 2004;48:525-546.
9. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
10. Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibitors parecoxib and valdecoxih after cardiac surgery. N Engl J Med 2005;352:1081-1091.
11. Finckh A, Aronson MD: Cardiovascular risks of cyclooxygenase-2 inhibitors: Where we stand now. Ann Intern Med 2005;142:212-214.
12. Simon AM, Manigrasso MB, O'Connor JP: Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-976.
13. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ: Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-1415.
14. Gerstenfeld LC, Thiede M, Seibert K, et al: Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003;21:670-675.
15. Reuben SS, Ekman EF: The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 2005;87:536-542.
16. Oelkers W: Adrenal insufficiency. N Engl J Med 1996;335:1206-1212.
17. Lamberts SW, Bruining HA, de Jong FH: Corticosteroid therapy in severe illness. N Engl J Med 1997;337:1285-1292.
18. Bromberg JS, Alfrey EJ, Barker CF, et al: Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 1991;51:385-390.
19. Friedman RJ, Schiff CF, Bromberg JS: Use of supplemental steroids in patients having orthopaedic operations. J Bone Joint Surg Am 1995;77:1801-1806.
20. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B: Perioperative glucocorticoid coverage: A reassessment 42 years after emergence of a problem. Ann Surg 1994;219:416-425.
21. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG: Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993;95:258-264.
22. Coursin DB, Wood KE: Corticosteroid supplementation for adrenal insufficiency. JAMA 2002;287:236-240.
23. Bathon JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593.
24. Sany J, Anaya JM, Canovas F, et al: Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993;20:1129-1132.
25. Perhala RS, Wilke WS, Clough JD, Segal AM: Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991;34:146-152.
26. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE: Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996;19:207-210.
27. Grennan DM, Gray J, Loudon J, Fear S: Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-217.
28. Rosandich PA, Kelley JT III, Conn DL: Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004;16:192-198.
29. Kalden JR, Schattenkirchner M, Sorensen H, et al: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arthritis Rheum 2003;48:1513-1520.
30. Johnson R, Charnley J: Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty Clin Orthop Relat Res 1979;444:174-177.
31. van der Heijde D, Klareskog L, Singh A, et al: Patient-reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: The TEMPO trial. Ann Rheum Dis 2006;65:328-334.
32. Weinblatt ME, Keystone EC, Furst DE, et al: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
33. Breedveld FC, Emery P, Keystone E, et al: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-155.
34. St Clair EW, van der Heijde DM, Smolen JS, et al: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443.
35. Phillips K, Husni ME, Karlson EW, Coblyn JS: Experience with etanercept in an academic medical center: Are infection rates increased? Arthritis Rheum 2002;47:17-21.
36. Bibbo C, Goldberg JW: Infection and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-335.
37. Giles JT, Bartlett SJ, Gelber AC, et al: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-337.
38. Fleischmann RM: Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003;42(suppl 2):ii29-ii35.
39. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-2293.
40. Cunnane G, Doran M, Bresnihan B: Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-363.